Dishman Pharmaceuticals and Chemicals, a contract research and manufacturing company based in India, has acquired Creapharm Parenterals, a subsidiary of French clinical supplies specialist Creapharm Group, for an undisclosed sum.
The deal was effected through Dishman’s wholly owned Swiss subsidiary Carbogen Amcis, which the Indian company acquired in 2006.
In a statement to the Bombay Stock Exchange, Dishman said Creapharm Parenterals, a contract development and manufacturing organisation specializing in liquid, semi-solid and injectable aseptic dosage forms, had changed its name to Carbogen Amcis SAS as part of the agreement.
The acquisition will extend Carbogen Amcis’s “comprehensive” range of development and manufacturing services by adding complementary formulation and lyophilisation services as well as sterile Good Manufacturing Practice-standard capabilities for the rapid supply of medicines, including highly potent compounds for preclinical and clinical trials, Dishman noted.
The company already runs manufacturing sites in the Netherlands, Switzerland and the UK, as well as India and China. Dishman has sales offices in India, China, Japan, Australia, the UK and the US.
The views expressed in the following comments are not those of PharmaTimes or any connected third party and belong specifically to the individual who made that comment. We accept no liability for the comments made and always advise users to exercise caution.